-The Economic Times The government is reviewing the norms for keeping buffer stocks of wheat and rice required at a particular time of the year to feed the public distribution system and welfare schemes. The demand for wheat and rice distributed through welfare schemes is expected to rise with the implementation of the food security law. "The government is looking at the issue and we are discussing it with different departments," KV Thomas,...

-Outlook India has long been the sleeping giant of global agriculture. But its misguided policies while boosting short-term output, yet may transform India into a food importer After decades on the sidelines of international Agricultural Trade, India was poised last year to become a major food supplier, overtaking traditional exporters of food grain and meat. This could prove to be flash in the pan. The sudden rise and fall of India...

-The Hindu A NABARD survey says middlemen funded by banks have kept growers captive to high-interest loans Jammu: Kashmir's acres of undulating apple orchards may soon be waste lands, a survey by the National Bank for Agriculture and Rural Development (NABARD) accessed by The Hindu shows. The Rs. 4,000-crore industry has been brought to its knees by a network of middle-order market functionaries comprising pre-harvest contractors (PHCs), commission agents (CAs) and wholesalers...

-The Times of India Direct transfer of benefits in cash to targeted beneficiaries of food and fertilizer subsidies could save an estimated Rs 60,000 cr and help trim the fiscal deficit which, in turn, may calm stubbornly high food inflation, a study by a government wing has shown. The study showed that policies to rein in food inflation would require winding down of the fiscal deficit, which has gone above 8% of...

-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...